Merck’s Keytruda Delivers Reduced Risk of Death in Adjuvant NSCLC

, , , , , , , ,

Merck announced that the company’s proposed treatment Keytruda for non-small cell lung cancer delivered positive results from a Phase III trial. 

Read more
/by